Najat Khan, Chief R&D Commercial Officer at RECURSION PHARMACEUTICALS, INC. (RXRX), sold 248,806 shares at $4.41 ($1.1M) on 2025-12-22, disclosed to the SEC on 2025-12-29.
Scheduled sale ($1.1M) by Chief R&D Commercial Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $4.41 | 124,403 | $549K | 50.0% |
| 2 | $4.41 | 124,403 | $549K | 50.0% |
| Total | $4.41 avg | 248,806 | $1.1M | 100% |
| Filing → |
| RXRX | SELL | 2026-03-11 | $189K | — | Filing → |
| RXRX | SELL | 2025-08-19 | $404K | — | Filing → |